Futher, corticosteroid-based treatments show effective anti-inflammatory efficacy as therapeutic agents for infectious diseases of the brains and in mouse model of multiple sclerosis, significantly down-regulating pro-inflammatory cytokines such as IL-1β, IL-6, IL-17, IFN-γ, and TNF-α [31, 83]. This evidence concerns the gene IL17A and multiple sclerosis.